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Effects of vitamin D on renal handling of calcium, magnesium, and
phosphate in the hamster. The effects of 1 ,25(OH)2D3 on the renal
handling of calcium (Ca), magnesium (Mg), and phosphate (Pi) in the
thyroparathyroidectomized (TPTX) hamster were studied in the pres-
ence of exogenous PTH. Clearance experiments were performed in the
following groups: acutely TPTX animals (group 1), acute TPTX plus
continuous infusion of PTH in low or high doses sufficient to (1) reduce
or (2) abolish the hypocalcemic effect of TPTX (groups 2 and 3,
respectively), and acute TPTX plus Ca (group 4) or Pi (group 5)
infusion. Each group was subdivided into control and experimental
subgroups. In all animals an initial control phase was followed by a
second phase in which experimental animals received an infusion of
l,25(OH)2D3 (1 U prime + 0.5 U/hr) while control animals received only
the ethanol vehicle. GFR and urine flow rate, were not altered signifi-
cantly in any of the groups. Pca and PM5 increased significantly in group
3 only. Group 2 showed an increase in FEc. (5.2 1.4 to 13.2 2.2%,
P < 0.001) and FEMS (7.3 1.3 to 17.3 2.2%, P < 0.001) in response
to 1 ,25(OH)2D3. Group 3 showed a significant increase in FEM5 only
(2.2 0.4 to 5.5 1.0%, P < 0.01). The changes in the control groups
were not significant. The administration of I ,25(OH)2D3 reduced phos-
phate excretion only in the presence of PTH. The FE decreased from
11.9 2.1 to 3.6 0.9% (P <0.001) in group 2 and 29.2 4.0 to 16.5
2.5% (P C 0.02) in group 3. The changes in the control groups were
not significant. However, infusion of Ca or Pi to TPTX animals to raise
plasma Ca and urinary Pi levels, respectively, did not elicit any
hypercalciuric or antiphosphaturic effects of 1 ,25(OH)2D,. These re-
sults suggest an antagonism by 1 ,25(OH)2D3 of the action of PTH
leading to the enhancement of Pi reabsorption and the inhibition of Ca
and Mg reabsorption. The effect on Ca and Mg transport may be direct
or may be secondary to the effect on Pi transport.
Effets de Ia vitamine D sur Ia conservation rénale de calcium,
magnesium et phosphates chez le hamster. Les effets du 1 ,25(OH)2D3 sur
Ia conservation rdnale de calcium (Ca), magnesium (Mg) et phosphates
(Pi) chez le hamster thyroparathyroidectomisds (TPTX) ont dté étudiés
en presence de PTH exogène. Des experiences de clearances ont eté
effectuCes dans les groupes suivants: animaux TPTX en aigu (groupe 1),
TPTX aigue plus perfusion continue de PTH a doses faibles ou élevees,
suffisantes pour, (1) reduire ou (2) abolir l'effet hypocalcémique de Ia
TPTX (groupes 2 et 3, respectivement), et TPTX aiguë plus perfusion
de Ca (groupe 4) ou de Pi (groupe 5). Chaque groupe Ctait subdivise en
sous-groupes contrôles et expérimentaux. Chez tous les animaux, une
phase contrôle initiale était suivie d'une seconde phase durant laquelle
les animaux expérimentaux recevaient une perfusion de 1 ,25(OH)2D3 (1
U de charge + 0,5 tJ/hr) alors que les animaux contrôles ne recevaient
que de l'Cthanol, Ic solvant. GFR et le debit urinaire n'etaient pas
altérés significativement dans aucun des groupes. Pca et Mg ont
augmenté significativement dans le groupe 3 seulement. Le groupe 2 a
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presente une élévation de FEc. (5,2 1,4 a 13,2 2,2%, P C 0,001) et
de FEMS (7,3 1,3 fl 17,3 2,2% P C 0,001) en réponse au
1 ,25(OH)2D3. Le groupe 3 a prCsentd une augmentation significative de
FEM5 seulement (2,2 0,4 a s,s 1,0%, P C 0,01). Les modifications
des groupes contrOles n'étaient pas significatives. L'administration de
1,25 (OH)2D3 a réduit l'excrétion de PTH. FEn a diminue de 11,9 2,1
a 3,6 0,9% (P <0,001) dans le groupe 2 et de 29,2 4,0 a 16,5 2,5%(P C 0,02) dans le groupe 3. Les modifications dans les groupes
contrOles n'etaient pas significatives. Cependant, la perfusion de Ca ou
de Pi aux rats TPTX pour augmenter les niveaux de calcemie ou de
phosphaturie, respectivement, n'entrainaient aucun effet hypercaliuri-
que ou antiphosphaturique du 1 ,25(OH)2D3 . Ces résultats suggérent un
antagonisme par le 1 ,25(OH)2D3 de l'action de la PTH aboutissant a une
stimulation de la reabsorption de Pi et a une inhibition de la
reabsorption de Ca et Mg. L'effet sur le transport de Ca et de Mg
pourrait étre direct ou pourrait être secondaire a l'effet sur Ic transport
de Pi.
The role of vitamin D and its active metabolites as one of the
major physiological regulators of mineral metabolism has been
well established. Whereas the effects of this hormone on the
skeleton and intestine have been well documented [1—4], the
intrinsic effects of vitamin D on the kidney remain unclear
[5—8j.
In the D-depleted state vitamin D appears to have an
anticalciuric effect [5—81 whereas in the D-replete state, the
presence of vasopressin may be required for an anticalciuric
effect to be seen [9]. Little or no evidence is available regarding
the action of vitamin D on the renal handling of magnesium
(Mg). Although evidence indicates that vitamin D may cause a
reduction in inorganic phosphate (Pi) excretion [5, 10—14], it is
not clear whether the presence of parathyroid hormone (PTH)
is required for this effect to be seen [5, 9, 12, 13].
The present studies were designed to further investigate the
influence of 1 ,25(OH)2D3 on the renal transport of calcium (Ca),
Mg, and Pi and the relationship of these effects to the action of
PTH. Experiments were carried out in the hamster, whose renal
transport of Ca has been shown to be highly sensitive to PTH
[15]. Using this model previously, we were able to show a
PTH-like effect of cyclic AMP, not only on the renal transport
of phosphate, but also on that of calcium and magnesium [161.
To avoid fluctuations in the plasma levels of PTH as a result of
either a direct or an indirect action of 1 ,25(OH)2D3 on its
secretion, studies were conducted in thyroparathyroidectom-
ized (TPTX) animals in the presence of differing doses of
exogenous PTH.
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Table 1. Experimental protocol
Experi-
Group N Parathyroid status
mental
phase
PCa
mEqiliter
1 A
B
8
13
TPTX Ethanol
l,25(OH)2D3
2.5
2.8
2 A
B
11
16
TPTX + Low-dose PTH Ethanol
l,25(OH)2D3
3.8
3.8
3 A
B
7
16
TPTX + High-dose PTH Ethanol
1,25(OH)2D3
4.2
4.4
4 A
B
5
6
TPTX + Ca infusion
(75 mEq/liter)
Ethanol
l,25(OH)2D3
4.7
4.6
5 A
B
4
4
TPTX + Pi infusion
(50 mi Na2HPO4,
NaH2PO4, 4:1)
Ethanol
l,25(OH)2D3
2.6
2.6
Abbreviations: N, total number of animals; A, control group; B,
experimental group; Pc, plasma calcium; TPTX, thyroparathyroid-
ectomized; Pi, phosphate.
Methods
Standard clearance experiments were performed on male
golden Syrian hamsters (Mesocricetus auratus) weighing 90 to
130 g, and allowed free access to food and water. The animals
were anesthetized intraperitoneally with mactin (18 mg/lOO g
body wt, Promonta, Hamburg, Germany) and tracheotomized.
Acute thyroparathyroidectomy was performed by cauterization
in all groups. Polyethylene catheters (PE 50) were inserted into
a jugular vein for the infusion of inulin and into a carotid artery
for blood sampling. Urine specimens were collected from a
catheter inserted into the bladder. Animals were placed on a
thermostatically controlled heated table to maintain body tem-
perature at 37°C. Surgical fluid losses were replaced by the
administration of 1% of body wt of 0.9% saline after the
completion of surgery. Throughout the experiments all animals
were infused with 3.5% inulin in 0.9% NaCI at 0.03 ml/min.
Clearance periods were commenced 2 hr post-TPTX and
consisted of two 60-mm phases (control and experimental)
separated by a 60-mm interval. The control (C) and experimen-
tal (E) phases each comprised two 30-mm urine collection
periods. A blood sample was taken at the end of each phase for
the determination of electrolyte concentrations. The red blood
cells of all animals were reinfused after being suspended in 0.9%
NaCI solution containing 2 mEq/liter of CaCl2 and 6 g% bovine
serum albumin.
The administration of 1 ,25(OH)2D3 was begun at the comple-
tion of the control phase with a priming dose of 1 U (65.6
pmoles) followed by 0.5 U/hr. The control animals were given
ethanol alone in the second phase (5 p1 prime followed by 5
j.dlhr) as this served as a vehicle for 1 ,25(OH)2D3 in the
experimental animals. The hamster groups used were as shown
in Table 1. To study the interaction of vitamin D and PTH,
groups 2 and 3 were infused throughout the study with purified
bovine PTH (Wilson Laboratory) following the completion of
the surgery. Group 2 animals were infused with PTH in doses
sufficient to reduce, but not prevent, the hypocalcemia resulting
from the TPTX. The results include an initial group of hamsters
infused with 2 U/hr of purified PTH (569 U/mg) and a subse-
quent group infused with a different batch of purified PTH at 0.8
U/hr (336 U/mg). These two doses produced similar levels of
plasma calcium (4.0 0.5 and 3.9 0.4 mEq/liter, respec-
tively). Group 3 animals were infused with PTH in doses which
restored normocalcemia in the TPTX animals. Again, lower
doses were required (2 to 3 U/hr) of the less purified PTH (336
U/mg) than those of the more purified hormone (3.3 to 5.0 U/hr)
to produce this effect. The reason for the disparity in the dose
levels required to produce the same effect appeared to be a
difference in the degree of purification in the two batches of
PTH. Additional studies indicate that this is probably attribut-
able to binding more purified PTH to the glassware used in the
infusion apparatus. The less purified hormone contains more
protein which serves as a carrier and thus reduces binding to the
glassware and tubing. Infusion of 1 U of highly purified PTH
(569 U/mg) raised PCa to 3.7 mEq/liter (N = 3) as compared to
4.4 mEq/liter (N = 3) when infused in 0.2% albumin solution.
Group 4 animals were infused throughout with 75 mEq/liters
CaCl2 added to the infusion solution to prevent the
hypocalcemia after TPTX. To elevate phosphate excretion in
TPTX animals, 50 m phosphate (Na2HPO4:NaH2PO4:4:l)
were added to the infusion solution (group 5). Mean plasma
phosphate concentration was increased to 2.05 mM.
Plasma and urine concentrations of inulin were determined
by the anthrone method 1171, calcium and magnesium by atomic
absorption spectrophotometry (model 303, Perkin Elmer,
Norwalk, Connecticut, USA), and sodium by flame photom-
etry. The determination of fractional excretion (FE) of calcium
and magnesium was based on a mean ultrafilterable value of
66.1% (SE 1.5, N = 16) and 79% (SE 1.2, N = 16),
respectively. These figures were obtained by ultrafiltration of
pooled blood from TPTX animals, TPTX animals infused with
different doses of PTH, and PTH plus l,25(OH)2D3 using
artificial membranes (Amicon, Lexington, Massachusetts,
USA) with the pH adjusted to 7.4. Neither the percent
ultrafilterable calcium, or that of magnesium, varied signifi-
cantly over the range of plasma concentrations obtained in
these studies.
Statistical analysis was performed by split-plot analysis of
variance [181, and the least significant difference test was used
to test for significance.
Results
Effects of 1,25(OH)2D3 in TPTX animals (group 1)
Neither the ethanol vehicle nor l,25(OH)2D3 caused signifi-
cant changes in the glomerular filtration rate (GFR) or urine
flow rate (Table 2). There was no significant change in plasma
Ca or FEa following the administration of the vehicle or
l,25(OH)2D3. Similarly, no changes in magnesium handling
were observed. A significant increase in plasma phosphate (1.5
to 1.9 mrvi, P < 0.05) occurred in the control group although
there was no significant change in FEE, in either the control or
experimental group.
Effects of 1,25(OH)2D3 in TPTX hamsters infused with graded
doses of PTH (groups 2 and 3)
The effects of vitamin D in the presence of exogenous PTH
are summarized in Tables 3 and 4. The dose of PTH used in
group 2 was such that it reduced but did not prevent the
hypocalcemic effect of TPTX. The GFR and urine flow rates
were not altered significantly in either the control or experimen-
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Table 2. Effects of 1 ,25(OH)2D3 in acutely TPTX hamstersa
Group
TPTX +
IA
Ethanol N = 8
F1'
Group lB
TPTX + l,25(OH)2D3 N = 13
C E C E F1'
Hct, % 51.8 0.6 50.4 0.4 NS 53,1 0.7 52.3 0.7 <0.02
Prt, g% 4.4 0.2 4.0 0.3 <0.02 4.5 0.2 4.1 0.2 <0.001
GFR, mi/mm 0.94 0.11 0.88 0.16 NS 0.77 0.07 0.79 0.09 NS
V. p.1/mm 5.4 0.7 4.0 0.8 NS 3.7 0.5 3.3 0.2 NS
PCa, mEqiliter 2.5 0.1 2.4 0.1 NS 2.9 0.1 2.8 0.1 NS
FLca, p.Eq/min 1.52 0.14 1.36 0.18 NS 1.45 0.14 1.38 0.14 NS
FEa, % 22.0 2.8 22.6 3.3 NS 18.5 2.1 19.4 2.6 NS
PMg, mEq/liter
FLMg, p.Eq/mmn
1,3 0.1
0.79 0.07
1.4 0.2
0.73 0.10
NS
NS
1.2 0.1 1.3 0.1
0.62 0.08 0.69 0.10
NS
NS
FEMg, %
P1, mM
21.5 3.3
1.5 0.3
20.3 2.4
1.9 0.4
NS
<0.05
21.0 1.9 16.6 2.9
1,3 0.2 1.5 0.1
NS
NS
FL, p.moies 1mm
FEpj, %
1.33 0.29
4.4 1.7
2.07 0.45
3.5 1.8
NS
NS
0.98 0.18 1.13 0.19
5.2 1.9 5,5 2,7d
NS
NS
PNa, mEq/liter
FENa, %
—
1.1 0.3
137.6 2.2c
1.0 0.4c NS
— 137.5 2.O
0.6 0.2C 0.3 O.l NS
Abbreviations: N, number of hamsters; TPTX, thyroparathyroidectomized; Hct, hematocrit; Prt, plasma protein; GFR, glomerular filtration
rate; V, urine flow rate; Pca, plasma Ca (Mg, Pi); FL, filtered load; FE, fractional excretion; C, control phase; E, experimental phase; NS, not
significant.
a The values are means si.
b The P values represent comparisons against the control phase.
P < 0.01 when compared to the same treatment phase in the control group (A).
dN 10.
eN = 5.
N= 6.
Table 3. Effects of 1 ,25(OH)2D3 in acutely TPTX hamsters infused with low-dose of PTHC
TPTX +
Group 2A
PTH (Low dose) +
Ethanol N = 11
pb
Group 2B
TPTX + PTH (Low dose) +
l,25(OH)2D3 N = 16
C E C E F1,
Hct, % 53.1 1.2 52.1 2.0 NS 53.7 0.8 52.7 0.9 <0.02
Prt, g% 4.4 0.1 4.1 0.2 NS 4.6 0.2 4.2 0.1 <0.01
GFR, mi/mm 1.0 0.1 1.1 0.1 NS 1.1 0.04 1.1 0.1 NS
V, p.1/mm 4.0 0.5 3.9 0.4 NS 4.5 0.6 4.7 0.5 NS
PCa, mEqiliter 3.8 0.2 3.8 0.2 NS 3.9 0.2 3.8 0.2 NS
FLEa, p.Eqlmin 2.32 0.25 2.57 0.16 NS 2.62 0.25 2.66 0.39 NS
FEca, % 5.6 1.3 7.5 2.1 NS 5.2 1.4 13.2 2.2c <0.001
PMg, mEqiliter 1.5 0.1 1.6 0.1 NS 1.5 0.1 1.5 0.1 NS
FLMS, p.Eq/min 1.34 0.26 1.38 0.11 NS 1.21 0.10 1.18 0.l3C NS
FEMg, % 11.1 3.1 10.6 2.7 NS 7.3 1.3 17.3 2.2C <0.001
mM 1.3 0.2 1.3 0.2 NS 1.1 0.1 1.3 0.1 <0.05
FL,, j.mo1es/min 1.39 0.22 1.30 0.10 NS 1.15 0.11 1.23 0.11 NS
FEpj, % 11.7 1.9 8.3 2.1 NS 11.9 2.1 3.6 0,9 <0.01
PNa, mEq/liter — 138.2 1.2" — 139.6 0.9e
FENa, % 1.2 0.1 0.8 0.2" NS 0.9 0.2 0.9 0.2 NS
Abbreviations are the same as those in Table 2.
a The values are means SE.
The P values represent comparisons against the control phase.
P < 0.01 when compared to the same treatment phase in the control group.
'N = 9.
C N = 13.
tal group. The administration of 1 ,25(OH)2D3 had no effect on
either Ca or FLEa but resulted in a highly significant increase in
FEca from 5.2 to 13.2% (P <0.001). Similarly, administration of
1 ,25(OH)D3 led to a significant increase in the FEMg from 7.3 to
17.3% (P < 0.001) without change in the plasma magnesium or
the FLMg. Both FEca and FEMg were significantly different
between the ethanol and 1 ,25(OH)2D3 groups in the experimen-
tal phases (P < 0.01). 1,25(OH)2D3 had an antiphosphaturic
effect in this group leading to a decrease in the FE1 from 11.9
to 3.6% (P < 0.001). This drop in FE1 was associated with a
small but significant increase in Pp, (1.1 to 1.3 mM, P < 0.05)
while the change in FL1 was not significant. The administration
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Table 4. Effects of 1 ,25(OH)2D3 in acutely TPTX hamsters infused with high-dose PTH
Group 3A Group 3B
TPTX + PTH (High dose) + TPTX + PTH (High dose) +
Ethanol N = 7 1,25(OH)2D3 N = 16
C E Pb C E pb
Hct, % 53.6 0.7 50.9 1.1 <0.01 52.7 0.8 51.5 0.6 <0.02
Prt, g% 4.3 0.1 3.9 0.2 <0.05 4.3 0.1 3.9 0.1 <0.001
GFR, mi/mm 1.1 0.1 0.8 0.1 NS 1.2 0.1 1.1 0.1 NS
V. pilmmn 6.4 1.5 4.6 0.9 NS 3.9 0.3 4.4 0.5 NS
1Ca, mEqiliter 4.2 0.1 4.7 0.2 <0.01 4.4 0.1 4.9 0.2 <0.001
FLEa, p.Eq/min 3.0 0.6 2.5 0.4 NS 3.1 0.1 3.6 0.2 NS
FEa, % 3.1 0.8 2.8 0.8 NS 1.7 0.2 2.7 0.6 NS
PMg' mEq/liter 1.5 0.1 1.8 0.1 <0.001 1.7 0.1 2.0 0.1 <0.001
FLMg, p.Eq/min 1.1 0.2 0.9 0.1 NS 1.4 0.1 1.5 0.1 NS
FEMg, % 6.0 1.8 5.6 1.9 NS 2.3 0.4 5.6 1.0 <0.01
mM 1.4 0.2 1.6 0.1 NS 1.5 0.2 1.8 0.2 <0.01
FL1, moles/min 1.7 0.4 1.2 0.1 NS 1.7 0.1 2.0 0.2 NS
FE1, % 21.9 4.2 15.8 3.5 NS 29.2 4.0 16.5 2.5 <0.02
PNa, mEqiliter — 140.2 2•3d NS — 141.0 1.3
FENa, % 1.6 1.4 1.4 04d NS 1.1 0.1 1.2 0.le NS
Abbreviations are the same as those in Table 2.
The values are means SE.
b The P values represent comparisons against the control phase.
P < 0.01 when compared to the same treatment phase in the control group.
d N = 6.
a N = 14.
Table S. Effects of 1 ,25(OH)2D3 in acutely TPTX hamsters infused with CaCl2a
Group 4A Group 4B
TPTX + CaCI2 (75 mEq/liter) + Ethanol TPTX + CaCI2 (75 mEq/liter) + 1 ,25(OH)2D3
C E N=6 C E N7
Hct, % 53.0 0.8 51.6 1.2 NS 51.8 0.4 51.4 1.6 NS
Prt, % 4.5 0.2 4.0 0.1 <0.02 4.7 0.1 3.9 0.2 <0.01
GFR, mI/mm 1.1 0.1 1.1 0.1 NS 1.0 0.1 1.0 0.1 NS
V, p1/mm 7.1 1.9 7.6 0.9 NS 5.2 0.6 8.3 2.0 NS
PCa, mEq/liter 4.7 0 3 4.6 0.2 NS 4.6 0.3 4.7 0.3 NS
FLca, j.Eq/min 3.1 0.5 3.1 0.4 NS 2.9 0.3 3.1 0.1 NS
FEca, % 35.3 4.5 43.8 2.3 NS 38.5 3.0 47.8 5.2 NS
PMg, mEqilirer 1.2 0.1 1.2 0.1 NS 1.2 0.2 1.2 0.1 NS
FLMg, i.Eq/min 0.9 0.1 0.9 0.1 NS 1.0 0.2 0.9 0.1 NS
FEMg, % 22.2 3.3 21.0 3.7 NS 27.2 2.2 22.7 3.8 NS
FENa, % 1.1 0.3 1.3 0.4 NS 1.0 0.1 1.7 0.3 NS
Abbreviations are the same as those in Table 2.
a Values are means SE.
of the vehicle did not have a significant effect on the handling of
any of these electrolytes. However, the difference in FEE,
between groups was not statistically significant. The handling of
sodium was not altered significantly in either group.
The effects of 1,25(OH)2D3 in the presence of higher doses of
PTH sufficient to restore Ca to almost normal (4.4 mEq/liter)
[16] are shown in Table 4 (group 3). While the hemodynamic
changes in this group were similar to those observed in group 2,
this dose of PTH further enhanced tubular reabsorption of
calcium elevating PCa to the levels seen in animals with intact
parathyroid glands. I ,25(OH)2D3 did not have a significant
effect on RCa, FLEa, OF FEca. Plasma Ca continued to increase
in both the control and experimental groups (4.2 to 4.7
mEq/liter, P < 0.001 and 4.4 to 4.9 mEq/liter, P < 0.001,
respectively). Although Pjg increased both in the control (1.5
tol.8 mEq/liter, P < 0.001) and experimental groups (1.7 to 2.0
mEq/liter), FEMg increased to a small but significant extent in
the experimental group (2.2 to 5.5%, P < 0.01) but not after the
vehicle (6.0 to 5.6%). FENa was not changed significantly in
either control or the experimental group.
Despite an increase in the baseline Pi excretion in both
groups with the higher dose of PTH, the antiphosphaturic effect
of l,25(OH)2D3 was still observed. A drop in the FE1 from 29.2
to 16.5% (P < 0.02) was associated with an increase in Ppj from
1.5 to 1.8 mrvi (P < 0.01). The changes in and FE1 of the
control group were not significant (1.4 to 1.6 m and 21.9 to
15.8%, respectively). However, the difference in FE1 between
groups was not significant.
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Table 6. Effects of I ,25(OH)2D3 in acutely TPTX hamsters infused with phosphatea
Effects of I,25(OH2D3 in TFTX, CaC12-infused hamsters
(group 4).
The results of studies of the role of Ca in the calciuric
response to 1 ,25(OH)2D3 are shown in Table 5. The infusion of
CaCl2 throughout the study prevented a fall in Ca following
TPTX. Despite normal ca levels, however, 1 ,25(OH)2D3 failed
to affect the tubular transport of Ca in the absence of PTH. The
changes in FEca in both the control and the experimental
groups were not significant. The changes in the handling of
magnesium were similar to those in group 1. Urinary Pi was
below the limits of detection in both groups.
Effects of I,25(OH)2D3 in TPTX, phosphate-infused hamsters
(group 5)
Table 6 summarizes the effects of I ,25(OH)2D1 in TPTX
hamsters in which baseline phosphate excretion was elevated
by the constant infusion of 50 mrvi Pi. Although this infusion
elevated Pp as well as no significant changes in Pi
handling were observed following the administration of
l,25(OH)2D3, while FE decreased significantly in the controls.
The changes in Pca and FLca in both the control and
1 ,25(OH)2D3 treated groups were not significant. Although
FEca decreased in both subgroups, the decrease was statisti-
cally significant only in the control group. However, the differ-
ence between groups was not significant. The administration of
1 ,25(OH)2D had no significant effect on either Mg or FEMg but
significantly increased FLMg. In the control animals FLM5 was
not changed, but Mg increased and FEM5 decreased signifi-
cantly.
Discussion
The present studies were performed with the objective of
evaluating the action of I ,25(OH)2D3 on the renal transport of
calcium and magnesium and to further elucidate the role of PTH
in these effects. As it has been suggested that I ,25(OH)2D3 may
affect PTH secretion [19, 20] experiments were carried out in
the absence of endogenous PTH. A constant dose of
l,25(OH)2D3 was used in all groups, whereas the dose of PTH
was varied. Available evidence suggests that the 2 U (130
pmoles) of I ,25(OH)2D3 vitamin D used is within the physio-
logical range in the rat. Using a similar dose, Raisz et al [4]
showed the enhancement of intestinal Ca transport, while
Chertow et al [201 demonstrated that 130 pmoles of
1,25(OH)2D3 inhibited PTH secretion in vitro and decreased its
plasma levels in vivo. Somewhat lower "physiological" doses
of I ,25(OH)2D3 for the rat have been reported by others;
Rizzoli, Fleisch, and Bonjour [211 found that 26 pmoles (11
ng)/day of 1 ,25(OH)2D3 given intraperitoneally were sufficient
to restore the intestinal Ca absorption in TPTX rats to the same
levels found in matched controls. Also, Lee et al [221 reported
that 13.5 ng/day of 1,25(OH)2D3 were the "physiological" dose,
because in normal rats the dose stimulated duodenal Ca absorp-
tion without affecting plasma calcium levels. However, much
higher doses of 1 ,25(OH)2D3 were required to stimulate Ca
absorption in various other intestinal segments [22]. Finally, in
vitamin D deficient rats the administration of 0.1 U of
I ,25(OH)2D3/hr for 6 hr decreased urinary phosphate excretion
in the presence of small "permissive" amounts of PTH [231. It
is possible that the physiological dose of 1 ,25(OHhD3 differs
between species, and to our knowledge, no data are available
for the hamster.
The results of the present studies regarding the effect of
1 ,25(OH)2D3 on the tubular transport of calcium and magne-
sium are striking. We have shown that in the TPTX hamster,
1 ,25(OH)2D3 increases calcium excretion in the presence of low
doses of PTH, but not in TPTX hamsters infused with higher
doses of PTH nor in TPTX animals in the absence of PTH, To
examine the possibility that severe hypocalcemia rather than
the absence of PTH could be responsible for the lack of the
calciuric response to I ,25(OH)2D3 in the TPTX hamsters, group
4 was infused with CaCl2. Despite the normocalcemia sustained
throughout the experiment, a calciuric response was not ob-
served in response to 1 ,25(OH)2D3 as had been seen in the
presence of low doses of PTH. The lack of an effect with
high-dose PTH probably reflects the overwhelming Ca-retaining
effect of PTH in this highly PTH sensitive species [15, 161. The
observation that 1 ,25(OH)2D3 has a similar effect on urinary
magnesium excretion, present even at high doses of PTH,
further suggests an anti-PTH action of 1 ,25(OH)2D3 in the
Group 5A
TPTX + 50 mM Pi + Ethanol (N = 4)
C E P
Group 4B
TPTX + 50 mM Pi + 1,25(OH)2D3 (N = 4)
C E P
Hct, % 52.0 1.1 53.0 1.2 NS 52.3 0.9 50.3 1.3 NS
Prt, % 4.7 0.2 4.2 0.2 <0.02 4.2 0.2 3.9 0.2 <0.02
GFR, mi/mm 0.8 0.2 0.8 0.1 NS 0.8 0.1 0.9 0.2 NS
V, pd/mm 4.0 1.0 4.3 1.2 NS 3.5 0.6 5.6 1.6 NS
pa, mM 2.2 0.4 2.6 0.5 NS 2.1 0.5 2.7 0.2 NS
FLn, j.smoies/min 1.85 0.61 2.14 0.60 NS 1.74 0.60 2.98 0.61 NS
PEa, % 61.2 20.1 44.9 ÷ 13.1 <0.05 60.7 12.4 58.0 12.2 NS
1ca, p.Eqlliter 2.6 0.2 2.6 0.2 NS 2.6 0.2 2.5 0.2 NS
FLca, p.Eq/mio 1.29 0.21 1.29 0.21 NS 1.22 0.22 1.51 0.22 NS
FEca, % 10.3 1.8 3.8 1.8 <0.05 6.1 1.8 3.8 0.8 NS
1M5 mEqlliter 1.1 0.1 1.4 0.1 <0.05 1.3 0.2 1.4 0.2 NS
FLM5, aEq/mmn 0.82 0.13 0.95 0.13 NS 0.84 0,13 1.22 0.14 <0.05
FEMg, % 11.3 1.4 4.4 ÷ 4.1 <0.05 9.2 1.6 5.9 1.6 NS
Abbreviations are the same as those in Table 2.
a Values are means 5E.
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kidney. The results of the present studies also suggest that
I ,25(OH)2D has an antiphosphaturic effect in the presence of
PTH. In the absence of PTH, regardless of the plasma Pi levels
or the baseline phosphate excretion, no such effect was seen.
An anticalciuric effect of vitamin D3 and 1 ,25(OH)2D3 has
been observed previously in D-depleted TPTX rats [5, 7, 8] and
dogs [61. In contrast, the animals in this study were not
D-depleted, and this may have obscured any direct tubular
effects of the vitamin D. 25(OH)D3 and l,25(OH)2D3 also were
shown previously to have an anticalciuric and antiphosphaturic
effect in D-replete, TPTX dogs [9, 13, 24, 25]. However,
vasopressin was administered continuously in some of these
animals [9, 13] and studies of Nseir, Szramowski, and Puschett
[9] suggest that the presence of vasopressin in TPTX animals
may be an absolute requirement for the above effects of vitamin
D to be seen. Vasopressin, when administered in pharmacologi-
cal doses, inhibits the tubular reabsorption of calcium [26],
phosphate, and sodium [27]. Therefore, it is possible that the
observed effects may be a result of an inhibitory effect of
vitamin D on the action of vasopressin [28]. Similarly,
25(OH)D3 has been shown to inhibit the phosphaturic effect of
calcitonin [29] and glucagon [30]. Thus, in addition to having a
direct tubular effect in D-deficient animals, vitamin D may
antagonize both the calciuric and phosphaturic actions of
vasopressin and the anticalciuric, antimagnesiuric, and
phosphaturic actions of PTH. It is also possible that this
inhibitory action is nonspecific and similarly affects other
polypeptide hormones acting in the kidney. However, our
experiments do not prove conclusively that a direct antagonism
exists between l,25(OH)2D3 and PTH. An alternative possibil-
ity is that the increased calcium and magnesium excretion are
secondary to the reduction in phosphate excretion since these
effects consistently occur together. However, we are not aware
of evidence that decreased phosphate excretion causes calciuria
and magnesuria, per se, and furthermore, in the experiments of
Nseir, Szramowski, and Puschett [9], decreased phosphate
excretion following 1,25(OH)2D3 was not accompanied by
calciuria.
Because the renal handling of Ca in the hamster is quantita-
tively different from that in humans, the relevance of these
studies to human physiology is not certain. However, clinical
data suggest that in such disorders as idiopathic hypercalciuria
[31] or hypercalciuric sarcoidosis [32], vitamin D excess might
cause inhibition of tubular Ca reabsorption. Although it is
difficult to show that hypercalciuria was not directly attribut-
able to hypercalcemia or even PTH suppression, it is possible
that increased circulating I ,25(OH)2D3 levels might increase
renal calcium clearance as well as promote intestinal calcium
absorption.
In summary, these results suggest that in the particular
circumstances of these experiments, 1,25(OH)2D3 antagonizes
the action of PTH in the kidney leading to the inhibition of Ca
and Mg reabsorption and enhancement of Pi reabsorption.
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